Non-invasive Biomarker Discovery for Pre-cervical or/and Cervical Cancer-HPV DNA and Other Biomarkers in Urine

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

300 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-07-20

Study Completion Date

2025-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this clinical trial is

1. To test the sensitivity and specificity of using HPV DNA from urine for the detection of pre-cervical or/and cervical cancer.
2. If HPV DNA is not a promising biomarker, other biomarkers will be explored.
3. To develop an effective and non-invasive detection method of the pre-cervical or/and cervical cancer. in Women with menstruation.

The main question it aims to answer is:

To validate whether HPV DNA from urine could be used as a non-invasive means for the detection of pre-cervical or cervical cancer

Participants will

1. Join the briefing session of the study
2. Sign the consent form and health questionnaire
3. Submit the cervical medical report(s) within 3 months or perform sponsored pap smear test
4. Collect the urine sample

If there is a comparison group: Researchers will compare The diseased group and the healthy group according to the medical reports they provided to see if HPV DNA from urine is a promising biomarker for the detection of pre-cervical or cervical cancer

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Clinical Evaluation of Detection of High Risk HPV in Urine

NCT05210348

Human Papillomavirus Infection Cervical Cancer Human Papilloma Virus +15 more

UNKNOWN

Non-invasive Biomarker Discovery for Pre-cervical or/and Cervical Cancer--ACTN4 and Other Biomarkers in Menstrual Blood

NCT06261879

Cervical Cancer CIN

RECRUITING NA

Blood and Urine HPVDNA as Minimally Invasive Biomarkers for Cervical Cancer Detection and Surveillance Following Treatment

NCT04743674

Cervical Cancer

RECRUITING

HR-HPV Multi-site Opportunistic Screening in Liaoning, China

NCT03178136

Cervical Cancer

UNKNOWN

Blood Biomarkers Based Screening for HPV-driven OPC

NCT06528353

Head and Neck Squamous Cell Carcinoma Anal Cancer Human Papilloma Virus

NOT_YET_RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

First stage of study: Female subjects within the age group will first attend an online research briefing session. After the online briefing session, the participant is provided an opportunity to join a private 1-to-1 consultation session, which enables the participant to be more familiar with the details of the research content, consent form, study procedures, and data confidentiality. If they have no further questions regarding the research content, consent form, etc. during the consultation session. They will sign the consent for participating in the study, they will fill in a questionnaire (attached) and clinic pap smear application form (attached). The questionnaire helps the research team to understand the subject's medical, gynaecological, and sexual histories; a unique identifier code will be given to each subject.

Second Stage of study: The research team will select the subjects based on the questionnaire answers. If the selected subjects have undergone pap test/ HPV test or coloscopy recently, within 3 months, they will submit the related medical record with the unique identifier number to us. If the selected subjects have not undergone pap test/ HPV test or coloscopy recently, within 3 months, they will be sponsored to Pap test or/and HPV genotyping or/and colposcopy at the designated hospitals or clinics. When their Pap test or/and HPV genotyping or/and colposcopy results are available, they or the designated hospitals/ clinics will send us the related medical reports with the unique identifier number.

Third Stage of Study: The participants will be further selected according to the medical records submitted. If the participants were selected to enter the third stage of the study, the selected subjects will submit their urine sample to us with a unique identifier number given.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cervical Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

SCREENING

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Collect HPV DNA from urine

Group Type EXPERIMENTAL

Collect HPV DNA from urine

Intervention Type DIAGNOSTIC_TEST

Use a sample collector to collect urine

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Collect HPV DNA from urine

Use a sample collector to collect urine

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Female aged between 18 to 65
* Have menstruation
* Had sex before
* Can read and write Chinese/ English
* Without taking any medication (Except nutritional supplements, traditional Chinese medicine, and health care products etc.)

Exclusion Criteria

• Subjects who used medication will be excluded from the sample collection. Moreover, subjects with visible signs of gynarcological infections (e.g. gonorrhea, trichomonas vaginalis) or suffered an HIV/ hepatitis B virus (HBV)-infection will be excluded.

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes